Literature DB >> 20467921

Sensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma.

Qin Huang1, Qiu-Xia Qu, Fang Xie, Jian-Ming Hu, You-Guo Chen, Xue-Guang Zhang.   

Abstract

CD40, a member of the tumor necrosis factor receptor superfamily, is widely expressed on various cell types. Some studies show that CD40 expression is related to several carcinomas, where its function remains largely unknown. This study investigated the expression of CD40 on cervical carcinoma and evaluated the effect of agnostic anti-CD40 mAb (5C11) on tumor cell line (SiHa). CD40 expression on the primary cervical carcinoma samples was detected by immunohistochemistry. Results showed that CD40 is commonly expressed in human cervical carcinoma, which is higher than that of normal cervix, cervical precancerous tissue and chronic cervicitis. Treatment of the SiHa cell with the agonistic anti-CD40 monoclonal antibody or Gemcitabine alone did not inhibit the proliferation of the SiHa cell in vitro, but the activation of CD40 on SiHa could enhance its sensitivity to Gemcitabine. Furthermore, CD40 activation blocked SiHa in the S phase, stimulated proapoptotic Bax and inhibited antiapoptotic Bcl-XL mRNA synthesis in the SiHa cell. Apoptosis in SiHa was associated with an increasing ratio of Bax to Bcl-XL in mRNA levels. It is concluded that use of the anti-CD40 mAb 5C11 in combination with chemotherapy may have significant therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467921     DOI: 10.1007/s12032-010-9538-8

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  19 in total

1.  An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line.

Authors:  Z H Zhou; J F Wang; Y D Wang; Y H Qiu; J Z Pan; W Xie; L Y Jiang; B Klein; X G Zhang
Journal:  Hybridoma       Date:  1999-12

Review 2.  CD40/CD154 interactions at the interface of tolerance and immunity.

Authors:  Sergio A Quezada; Lamis Z Jarvinen; Evan F Lind; Randolph J Noelle
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

3.  Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines.

Authors:  Bohuslav Melichar; Rebecca Patenia; Stacie Gallardo; Karolina Melicharová; Wei Hu; Ralph S Freedman
Journal:  Gynecol Oncol       Date:  2006-12-12       Impact factor: 5.482

4.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

5.  Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.

Authors:  M C Wei; W X Zong; E H Cheng; T Lindsten; V Panoutsakopoulou; A J Ross; K A Roth; G R MacGregor; C B Thompson; S J Korsmeyer
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

6.  CD40-activated apoptotic tumor cell-pulsed dendritic cell could potentially elicit antitumor immune response: involvement of up-regulation of B7-H3 expression.

Authors:  Cheng Chen; Yi-Bei Zhu; Qiu-Xia Qu; Yan Ge; Jian-An Huang; Yong Wang; Xue-Guang Zhang
Journal:  J Immunother       Date:  2009-01       Impact factor: 4.456

7.  Sensitization of multiple myeloma and B lymphoma lines to dexamethasone and gamma-radiation-induced apoptosis by CD40 activation.

Authors:  Zhao-Hua Zhou; Qin Shi; Jiang-Fang Wang; Yong-Jing Chen; Yu-Mei Zhuang; Jian-Zhong Pan; Chang-Shao Xu; Chun-Jian Qi; Xue-Guang Zhang
Journal:  Apoptosis       Date:  2005-01       Impact factor: 4.677

8.  Preparation and characterization of a novel chimeric antibody against human CD40 with the potential to inhibit Daudi cell proliferation.

Authors:  Qiu-Xia Qu; Yan Ge; Yong-Jin Chen; Cheng Chen; Yu-Hua Qiu; Xue-Guang Zhang
Journal:  Hybridoma (Larchmt)       Date:  2009-04

9.  Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity.

Authors:  Donatella Del Bufalo; Daniela Trisciuoglio; Marco Scarsella; Uwe Zangemeister-Wittke; Gabriella Zupi
Journal:  Oncogene       Date:  2003-11-20       Impact factor: 9.867

10.  Bcl-XL inhibits membrane permeabilization by competing with Bax.

Authors:  Lieven P Billen; Candis L Kokoski; Jonathan F Lovell; Brian Leber; David W Andrews
Journal:  PLoS Biol       Date:  2008-06-10       Impact factor: 8.029

View more
  1 in total

1.  Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein.

Authors:  Xiansheng Lin; Mei Huang; Fang Xie; Hangcheng Zhou; Ji Yang; Qiang Huang
Journal:  Oncotarget       Date:  2016-10-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.